Early Detection of Prostate Cancer in 2007

Schröder, Fritz H.; Carter, H. Ballentine; Wolters, Tineke; Bergh, Roderick C.N. van den; Gosselaar, Claartje; Bangma, Chris H.; Roobol, Monique J.

doi:10.1016/j.eururo.2007.10.047

Cited by 144 publications

(70 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, no statistically significant difference in regard to patients' age was found between men with subsequent cancer findings and those without subsequent cancer (64.2G1.0 vs 64.8G1.1, PZ0.28), suggesting that age probably does not influence serum levels of EPCA in patients with isolated HGPIN. Although serum PSA and its isoforms have been of continuous interest with regard to early detection and screening for PCa (Crawford & Abrahamsson 2008, Schröder et al 2008, Jansen et al 2009), limitations in the sensitivity and specificity for the prediction of PCa are well understood (Welch et al 2005, Steuber et al 2008. Serum PSA level, PSA velocity, and abnormal DRE findings as parameters of clinical importance have more recently been evaluated to predict the presence of PCa among men with HGPIN; however, the results were still conflict (Cheng et al 2004, Moore et al 2005, Herawi et al 2006, Akhavan et al 2007, Loeb et al 2007.…”

Section: Discussionmentioning

confidence: 99%

Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia

Zhao

Zeng²

2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

Early prostate cancer antigen (EPCA) has been recently suggested as a novel biomarker in malignant and premalignant lesions of the prostate. This study was to examine serum expression of EPCA and to further clarify the relationship between initial serum EPCA levels and the presence of subsequent cancer in the individuals with isolated high-grade prostatic intraepithelial neoplasia (HGPIN). An indirect ELISA was used for initial serum EPCA measurement in 112 men with isolated HGPIN, who were enrolled and completed a follow-up of R5 years. All patients had a detectable concentration of EPCA in the initial serum, with a mean of 0.64G0.13 absorbance at 450 nm. Thirty-three patients had an initial serum EPCA level of R1.10, in which 31 cases were subsequently identified as having prostate cancer on follow-up. However, in the remaining 79 cases, serum EPCA levels were all !1.10, and none was diagnosed with cancer later. Statistical analysis showed a significantly higher serum ECPA level in isolated HGPIN patients with subsequent cancer than those without cancer (P!0.001). The area under the receiver operating characteristic curves showed that serum EPCA level had better predictive accuracy of cancer onset on follow-up than prostate specific antigen velocity and abnormal digital rectal examination findings. Furthermore, univariate and multivariate Cox regression analyses demonstrated the predictive performance independently by initial serum EPCAR1.10 absorbance (relative risk, 3.32; 95% confidence intervals, 2.62-5.03, P!0.001). These preliminary findings first show the potential of serum EPCA to serve as a significant predictor for subsequent cancer in isolated HGPIN.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia

Zhao

Zeng²

2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…This approach contrasts with that of our study, in which the only difference was the reference standard. The finding of a decrease in cancer detection caused by application of the WHO 96/670 calibration may also have positive implications in light of the current discussions on limiting PCa overdetection and subsequent overtreatment (31)(32)(33)(34). Because the group of missed cancers contains significantly fewer tumors with a high stage or a high Gleason score and more tumors with favorable characteristics (Tables 3 and 4), missing these cancers may not have clinical consequences and so may limit the overdetection and overtreatment of PCa.…”

Section: Discussionmentioning

confidence: 99%

Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection

Jansen¹,

Roobol²,

Bangma³

et al. 2008

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…In addition, this earlier diagnosis increases the number of patients presenting with clinically organ-confi ned disease and therefore, it has led to an increase of the number of candidates for radical prostatectomy (1,2). Radical prostatectomy has been associated with complications such as postoperative urinary incontinence and erectile dysfunction.…”

Section: Introductionmentioning

confidence: 99%

Effect of Mesenchymal Stem Cells Associated to Matrixen on the Erectile Function in the Rat Model with Bilateral Cavernous Nerve Crushing Injury

et al. 2012

View full text Add to dashboard Cite

Objectives:To evaluate the effect of mesenchymal stem cells (MSCs) and MSCs mixed with Matrixen as a cell carrier on the erectile dysfunction caused by bilateral cavernous nerve crushing injury. Materials and Methods: White male Sprague-Dawley rats were divided into 4 groups: sham-operated control group (n = 5), bilateral cavernous nerve crushing group (BCNC group, n = 10), BCNC administered with MSCs group (n = 10,1x106 in 20 µL), BCNC administered with Matrixen group (n = 10.1x106 in 20 µL), BCNC administered with MSCs/Matrixen group (n = 10.1x106 in 20 µL). After functional assessment at 4 weeks, major pelvic ganglion (MPG) and penile tissue were collected. Immunofl uorescent staining of MPG was performed with PKH26 and Tuj1. Western blot analysis of endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) were done in corpus cavernosum. Results: ICP/MAP ratios of BCNC with MSCs and MSCs/Matrixen groups were significantly increased compared with BCNC and BCNC with Matrixen group. Moreover, ICP/ MAP ratios of MSCs/Matrixen group were signifi cantly increased compared with BCNC with MSCs group. In MPG, the more implantation of MSCs and increased expression of nerve cells were observed in MSCs/Matrixen group compared with BCNC with MSCs group. Signifi cant increase expression of eNOS and nNOS was also noted in BCNC with MSCs/Matrixen group. Conclusion: The erectile function was more preserved in MSCs/Matrixen group compared with the administration of MSCs alone in the rats with bilateral cavernous nerve crushing injury. Therefore, we consider that the use of transplant cell carrier such as Matrixen may help the implantation of MSCs and improve the therapeutic effect of MSCs. INTRODUCTIONDiagnosis of prostate cancer has been elevating due to the increase in prostate-specifi c antigen (PSA) screening. In addition, this earlier diagnosis increases the number of patients presenting with clinically organ-confi ned disease and therefore, it has led to an increase of the number of candidates for radical prostatectomy (1,2). Radical prostatectomy has been associated with complications such as postoperative urinary incontinence and erectile dysfunction. Erectile dysfunction is a bothersome complaint among pa-

show abstract

Early Detection of Prostate Cancer in 2007

Cited by 144 publications

References 38 publications

Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia

Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia

Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection

Effect of Mesenchymal Stem Cells Associated to Matrixen on the Erectile Function in the Rat Model with Bilateral Cavernous Nerve Crushing Injury

Contact Info

Product

Resources

About